Sulforaphane Supplements Contract Manufacturing Platform
Sulforaphane products can be developed from different active systems and delivered in different formats. The starting configuration depends on the target dose, ingredient system, product positioning, stability requirements and production economics.
Active Systems
- Glucoraphanin (GR) · Sulforaphane · Broccoli Sprout Extract · GR + Myrosinase
- Select the active system according to the intended product concept, target specification and conversion requirements.
Dosage Forms
- Capsules · Tablets · Powders · Stick Packs · Softgels where formulation-compatible
- Format selection considers serving size, powder characteristics, stability, manufacturing feasibility and target market positioning.
Advanced Delivery
- Liposomal · Capsule-in-Capsule · Delayed Release
- Advanced delivery systems are considered when they address a defined formulation, stability, separation or product-positioning requirement.
Explore Liposomal Sulforaphane Manufacturing →
From Formula to Commercial Batch
- Feasibility Review → Sample Development → Pilot / Process Confirmation → Commercial Production → QC Release
- The development process is designed to identify formulation, fill-weight, compatibility and stability issues before commercial-scale production.
What Can Be Customized at KS Nutripharma®?
You can start with an existing formula or a product concept. Key parameters can be reviewed and adjusted during development.
| Development Parameters | Typical Options |
| Active system | SFN · GR · GR + myrosinase · Broccoli sprout extract |
| Target dose | Defined by serving or daily intake target |
| Capsule | HPMC · Gelatin · #00 · #0 · #1 |
| Delivery | Standard · Liposomal · Capsule-in-Capsule · Delayed Release |
| Supporting ingredients | Vitamins · Minerals · Botanical extracts |
| Dosage form | Capsule · Tablet · Powder · Stick Pack |
| Packaging | Bottle · Blister · Sachet · Custom packaging |
| Target market | US · EU · UK · Canada · APAC · Other |
Manufacturing Capacity & Verifiable Credentials
| 19+ Years Nutraceutical Manufacturing | 81,000 m² GMP-Compliant Facility | 12 Production Lines |
| 500+ Brands Served Globally | 60+ Export Markets | 2 Dedicated R&D Centers |
| 5 M Capsules / Day | 2M Softgels / Day | 12M Tablets / Day |
| 2 M Gummies / Day | 7 International Certifications | 100% Batch Traceability |
Mature Formulations
These broccoli extract supplement formulations are designed for brands targeting immune health, healthy aging, detoxification, and cellular wellness. If you don’t know how to choose a market position, you can shift to our sulforaphane health benefits page.
Key Positions:
- Daily immune support
- Antioxidant protection
- Suitable for year-round wellness products
Key Positions:
- Phase II detoxification support
- Liver health positioning
- One of the most established antioxidant combinations
Key Positions:
- Premium healthy aging formula
- Cellular defense support
- Designed for high-value wellness brands
Key Positions:
- Joint mobility support
- Oxidative stress management
- Enhanced absorption strategy
Key Positions:
- Cellular resilience
- Healthy aging
- Biohacking & longevity positioning
- Custom ingredient combinations
- Vegan & vegetarian capsules
- Clean label formulations
- Allergen-free options
- Multiple dosage strengths
- Regulatory market adaptation
Emerging Formulation Trends
Trending Concepts for Premium Supplement Brands
Key Positions:
- Longevity
- Cellular health
- Healthy aging
- NRF2 activation
Key Positions:
- Detox support
- Liver health
- Urban wellness
- Environmental protection
Key Positions:
- Cognitive health
- Focus
- Brain aging
- Neuroprotection
Key Positions:
- Exercise recovery
- Oxidative stress
- Muscle recovery
- Active lifestyle
Key Positions:
- Hormone balance
- Estrogen metabolism
- Women’s wellness
Key Positions:
- Cellular antioxidant
- Glutathione production
- Premium wellness
Compatible Ingredients by Function
The following ingredients have been validated by our formulation science team as compatible with sulforaphane and broccoli extract in multi-ingredient supplements. This list is based on stability compatibility testing, known pharmacokinetic interactions, and demonstrated mechanistic synergy.
- DIM
- Calcium D-Glucarate
- Chaste Tree Berry
- Evening Primrose Oil
Formulation Compatibility: What Should Be Reviewed?
Not every ingredient is automatically suitable for a Sulforaphane formula. When combining Sulforaphane, glucoraphanin, myrosinase, vitamins, minerals, or botanical extracts, compatibility should be assessed based on the actual raw-material specifications and finished formulation.
Key areas to review include:
- Myrosinase-sensitive combinations — Ingredients or processing conditions that may affect enzyme activity should be evaluated in GR + myrosinase systems.
- Moisture-sensitive combinations — Hygroscopic ingredients can affect powder flow, blend uniformity, capsule filling, and stability.
- Different release or pH requirements — Ingredients with substantially different processing or release requirements may require formulation adjustment or physical separation.
- High-load multi-ingredient formulas — Adding multiple actives can create capsule-capacity, flowability, compatibility, or content-uniformity constraints.
The objective is not to maintain a fixed “avoid” list, but to identify potential interactions before the formula is finalized and scaled up.
Sulforaphane Dosage Forms: Which Format Fits Your Product?
The right dosage form depends on the active system, target serving size, powder characteristics, stability requirements, product positioning, and cost target. The options below are starting points for formulation development rather than fixed recommendations.
Hard capsules are often a practical starting format for glucoraphanin (GR), GR + myrosinase, broccoli sprout extracts, and other dry Sulforaphane systems.
They are useful when the formula requires powder flexibility, low development complexity, or separation of selected ingredients. HPMC and gelatin shells can be considered according to market positioning and product requirements.
Consider capsules when:
- The formula is primarily powder-based
- The target serving fits practical capsule capacity
- Ingredient compression is not ideal for tablets
- HPMC or gelatin is preferred
- The formula may require capsule-in-capsule, pellet, or granule filling
Technical considerations:
Powder density · Flowability · Moisture sensitivity · Fill weight · Capsule size · Blend uniformity
Related: Sulforaphane Capsules Manufacturer →
Softgels are generally more appropriate when the active system is formulated in an oil-based or lipid-compatible fill rather than as a conventional dry powder.
They can provide a different product appearance and swallowing experience, but the formulation must be compatible with the softgel fill system and shell.
Consider softgels when:
- The active system is suitable for an oil-based formulation
- A lipid-based delivery concept is required
- The target product positioning favors softgels
- The formula can meet fill and shell compatibility requirements
Technical considerations:
Oil solubility / dispersion · Fill viscosity · Shell compatibility · Oxidative stability · Encapsulation · Leakage and seal integrity
For conventional dry GR or broccoli extract formulas, hard capsules may be a more straightforward starting point.
Tablets can be considered when the formula has sufficient compression characteristics and the target serving requires a relatively dense solid dosage form.
They may be suitable for cost-sensitive, high-volume SKUs where tablet compression does not compromise the stability or performance of the active system.
Consider tablets when:
- The formula has suitable compressibility
- A higher-density dosage form is preferred
- Unit economics are a major consideration
- Tablet size and appearance fit the product concept
- Coating or controlled-release functionality is required
Technical considerations:
Compression behavior · Lubricant compatibility · Disintegration · Dissolution · Heat and mechanical exposure during compression
For GR + myrosinase systems, compression conditions and processing exposure should be assessed before selecting tablets as the final format.
Advanced Capsule & Delivery Technologies
Some Sulforaphane products require more than a conventional capsule or tablet configuration. The delivery technology should be selected when it solves a defined formulation, stability, or product-positioning requirement.
A liposomal system can be considered when a phospholipid-based delivery approach is part of the product concept.
Development may involve:
Phospholipid selection · Particle size · PDI · Encapsulation efficiency · Physical stability · Capsule compatibility
Suitable for:
Premium positioning · Differentiated delivery concepts · Advanced formulation projects
Capsule-in-capsule creates physical separation between selected ingredients within the same serving.
It can be considered when:
- GR and myrosinase have different stability requirements
- Hygroscopic and moisture-sensitive components need separation
- Different release profiles are required
- Physical separation is technically preferable to a single blend
The trade-off is higher manufacturing complexity, cost, and potentially larger capsule size.
Delayed-release or enteric technology can be evaluated when the product has a defined release requirement.
This option introduces additional coating, dissolution, stability, and process considerations and should therefore be selected for a specific product requirement rather than simply as a premium feature.
Quick Format Selection Guide
| Product Requirements | Starting Format | Main Reason |
|---|---|---|
| Straightforward GR / GR + myrosinase formula | Hard capsules | Flexible powder filling and relatively simple development |
| Higher powder load | #00 capsule / multiple capsules / powder | More practical serving capacity |
| Cost-sensitive, high-volume SKU | Tablet | Higher density and potential unit-cost advantage |
| Oil-based / lipid-compatible system | Softgel | Better suited to liquid or lipid fills |
| Large serving size | Powder / stick pack | Avoids capsule volume limitations |
| Portable single-serving product | Stick pack | Convenient powder delivery |
| Physical ingredient separation | Capsule-in-capsule | Separates components within one serving |
| Phospholipid delivery concept | Liposomal capsule | Differentiated delivery architecture |
| Defined GI release requirements | Delayed-release / enteric | Controlled release location |
Broccoli Seed Extract vs. Broccoli Sprout Extract vs. Mature Broccoli Extract
| Source | Typical Glucoraphanin Level | Key Characteristics | Best Applications |
|---|---|---|---|
| Mature Broccoli Extract | Typically below 0.5% | Rich in naturally occurring vitamins, minerals, dietary fiber, flavonoids, and phytonutrients, but contains only trace levels of glucoraphanin. Suitable for general vegetable nutrition rather than high-potency sulforaphane formulations. | Daily wellness supplements, green food blends, multinutrient botanical formulas |
| Broccoli Seed Extract | 10–20% standardized glucoraphanin | Highest concentration of glucoraphanin with excellent batch consistency. Widely used as the primary raw material for premium standardized sulforaphane supplements. | Premium retail, practitioner-grade, and clinically positioned products |
| Broccoli Sprout Extract | 10–30% standardized glucoraphanin | Produced from 3–5 day broccoli sprouts. Naturally rich in glucoraphanin and may retain endogenous myrosinase depending on processing technology. Increasingly favored for premium and science-backed formulations. | Healthy aging, NRF2 activation, cellular health, and high-potency formulations |
KS Nutripharma Recommendation
For most commercial sulforaphane supplements, we recommend standardized broccoli seed extract or broccoli sprout extract containing 10–13% glucoraphanin, as these materials provide the best balance of active compound concentration, batch consistency, manufacturing stability, and commercial scalability.
Mature broccoli extract remains a valuable botanical ingredient for whole-food nutrition products, but it is generally not the preferred source for high-potency sulforaphane supplements due to its naturally low glucoraphanin content.
Standardized Glucoraphanin
Glucoraphanin is the most widely used specification for commercial sulforaphane supplements because of its superior stability and manufacturing practicality.
Typical commercial specifications include:
- <0.5% – Mature broccoli extract, primarily used for whole-food nutritional products
- 5% – Entry-level standardized formulations
- 10% – Mainstream commercial specification for broccoli seed or sprout extract
- 13% – Premium industry benchmark widely adopted by science-backed brands
- 20% – Practitioner-grade formulations
- 30%+ – Customized high-potency ingredients
Most commercial OEM projects utilize 10–13% standardized glucoraphanin, offering the best balance between efficacy, stability, and production cost.
Standardized Sulforaphane
Although active sulforaphane can be supplied as a standardized ingredient, it is inherently unstable and significantly more difficult to manufacture than glucoraphanin.
Typical commercial specifications include:
- 0.1–0.5% – Naturally generated sulforaphane
- 1% – Standard activated ingredient
- 2%+ – Specialty material requiring advanced stabilization technologies
For this reason, most commercial supplements are formulated with standardized glucoraphanin together with myrosinase rather than pre-activated sulforaphane, providing better shelf stability while allowing sulforaphane to be generated after consumption.
Myrosinase Activity
Myrosinase is the enzyme responsible for converting glucoraphanin into biologically active sulforaphane. Without sufficient enzyme activity, the conversion efficiency may be significantly reduced.
Typical commercial activity levels include:
- 1,000–5,000 U/g – Entry-level synergistic formulations
- 10,000–30,000 U/g – Mainstream commercial formulations
- 50,000+ U/g – High-activity premium formulations requiring specialized stabilization
Depending on formulation strategy, myrosinase may be supplied as a purified enzyme or naturally retained through carefully processed broccoli sprout powder.
Recommended Specifications by Product Positioning
| Product Positioning | Recommended Specification | Typical Daily Dose | Typical Applications |
| Value | 5–10% | 10–15 mg | Daily wellness |
| Mainstream | 10–13% | 15–30 mg | Retail brands |
| Premium | 13–20% | 30–50 mg | Practitioner |
| Clinical | 20%+ | 50–100 mg | Clinical nutrition |
KS Nutripharma Selection Principles
When developing commercial sulforaphane supplements, we recommend evaluating raw materials based on total formulation performance rather than specification alone.
✔ Select standardized glucoraphanin instead of relying solely on extract ratios.
✔ Evaluate the effective glucoraphanin delivered per serving, not just the percentage specification.
✔ Choose the appropriate raw material source (seed, sprout, or mature broccoli) according to your product positioning.
✔ Consider myrosinase activity, stability, and manufacturing feasibility together when selecting formulation strategies.
✔ Request HPLC-verified specifications, stability data, and complete batch traceability before commercialization.
Specification Does Not Equal Daily Intake
A higher specification does not automatically result in a more effective product. The actual amount of glucoraphanin delivered per serving is often more important than the percentage listed in the raw material specifications.
For most commercial formulations, a daily intake of 15–30 mg of standardized glucoraphanin provides a practical balance between efficacy, formulation flexibility, and production cost.
Sulforaphane products can be affected by active form, moisture, processing exposure, enzyme activity, powder characteristics and packaging. These factors are reviewed during formulation development so that potential issues can be identified before commercial production.
Active Stability
Free sulforaphane is sensitive to heat, moisture and oxidation. Development therefore reviews processing exposure, excipient selection, raw-material specifications and packaging requirements. Glucoraphanin (GR) is generally more stable during processing, but GR-based formulas require separate consideration of the myrosinase system when conversion to sulforaphane is part of the product concept. (Sulforaphane vs Glucoraphanin)
Moisture Control
Moisture control is particularly important for hygroscopic extracts and enzyme-containing systems. For capsule production, the manufacturing specification identifies ≤45% RH during encapsulation as a controlled condition. Finished-product packaging is selected according to moisture sensitivity, container barrier properties, headspace and desiccant requirements.
GR + Myrosinase Activity
When myrosinase is included, enzyme activity becomes a defined quality parameter rather than an assumed characteristic of the formula. Activity can be evaluated using a spectrophotometric sinigrin-hydrolysis method at incoming raw-material, in-process and finished-product stages where required by the approved specification.
Powder Flow & Fill Performance
Broccoli sprout extracts and other Sulforaphane raw materials can vary substantially in particle size, bulk density and flowability. A preliminary bulk-density range of approximately 0.3–0.6 g/mL may be used for planning, but actual fill weight is confirmed from measured bulk / tapped density and filling trials. Powder-flow characteristics can be evaluated with reference to USP <1174> where applicable.
Multi-Ingredient Compatibility
Vitamins, minerals and botanical extracts can change moisture behavior, flowability, blend uniformity or capsule capacity. Compatibility is therefore reviewed before commercial production. If ingredients have materially different stability requirements, physical separation or a different delivery configuration may be more appropriate than forcing all components into one blend.
Packaging & Stability
Packaging is selected together with the formulation rather than after the formula has been finalized. Depending on the product, stability programs may include accelerated testing at 40°C / 75% RH, real-time monitoring, active-assay retention, myrosinase activity, moisture and physical characteristics.
The exact control limits and testing plan are defined by the approved raw-material specification, finished-product specification, target market and commercial packaging configuration.
What This Means For You?
A Sulforaphane formula should not be approved simply because the nominal active dose fits inside a capsule. Active stability, enzyme activity, powder behavior, fill weight, ingredient compatibility and packaging protection need to work together. These checks are intended to identify technical issues before the project moves into full commercial production.
Have an existing formula or target dose?
Send us the active specification, target dosage, capsule format and supporting ingredients for an initial feasibility review.
Sulforaphane supplements may use glucoraphanin (GR), sulforaphane itself, or a GR + myrosinase system. These approaches are not technically interchangeable because the active form, conversion mechanism and formulation requirements are different.
1. Glucoraphanin (GR)
Glucoraphanin is the precursor used in many broccoli-based Sulforaphane products. GR itself is relatively stable compared with free sulforaphane, which can make it practical for certain finished-product formats.
Development consideration:
The product specification should define GR content and whether a myrosinase source is included or expected to provide conversion.
↓
2. Myrosinase
Myrosinase is the enzyme responsible for converting glucoraphanin into sulforaphane.
Development considerations:
When myrosinase is included in the formulation, enzyme activity becomes an additional quality parameter. Processing conditions, moisture exposure and ingredient compatibility may therefore affect the finished product.
↓
3. Sulforaphane (SFN)
Sulforaphane is the isothiocyanate generated through the enzymatic conversion of glucoraphanin.
Development consideration:
Formulas using free sulforaphane require greater attention to processing and storage conditions because SFN is more reactive than its GR precursor.
What This Means for Product Development
| Active System | Main Development Focus | Typical Consideration |
|---|---|---|
| GR | GR specification and stability | Suitable when the product is built around a stable precursor system |
| GR + Myrosinase | GR content + enzyme activity | Requires control of enzyme activity and formulation compatibility |
| Free SFN | SFN assay + stability | Greater attention to moisture, heat, oxidation and packaging |
| Broccoli Sprout Extract | Extract specification + active standardization | Actual GR / SFN profile depends on the raw-material specification |
The appropriate system depends on the target active, dosage, raw-material specification, delivery format, stability requirements and product concept.
Glucoraphanin (GR) is the precursor used in many commercial Sulforaphane formulations, while sulforaphane (SFN) is the isothiocyanate generated through enzymatic conversion. The two ingredients have different stability and formulation characteristics.
KS Nutripharma operates a dedicated sulforaphane production platform — not a general-purpose line adapted for the ingredient. Every step below is optimized specifically for the stability requirements of glucoraphanin, myrosinase, and sulforaphane:
End-to-End Process Flow
| Process Step | Control Parameter | Equipment / Method |
| 1. Raw Material Qualification | Glucoraphanin assay, myrosinase activity, heavy metals, microbial | HPLC-UV, spectrophotometric assay, ICP-MS, USP <61>/<62> |
| 2. Extract Standardization | Potency confirmation; particle size distribution | HPLC verification; laser diffraction analysis |
| 3. Particle Engineering | Surface area control; blend uniformity optimization | Micronization (if required); blend homogeneity testing |
| 4. Humidity-Controlled Blending | RH < 30%; temperature < 35 degrees C | Dehumidified suite; jacketed blender with temperature monitoring |
| 5. Myrosinase Protection | Enzyme activity preservation; excipient compatibility | Low-shear blending; validated enzyme stabilizers |
| 6. Encapsulation / Tableting | Compression force; fill weight uniformity; seal integrity | Automated encapsulation; in-process weight checks |
| 7. Nitrogen Packaging | Residual oxygen < 3%; desiccant integration | Nitrogen flushing line; oxygen headspace analyzer |
| 8. Stability Validation | Accelerated (40 degrees C / 75% RH) and real-time (25 degrees C / 60% RH) | ICH Q1A stability chambers; HPLC potency tracking |
| 9. Commercial Production | Batch records; ERP traceability; QA release | cGMP batch documentation; Certificate of Analysis |
Each process step includes defined Critical Process Parameters (CPPs) and in-process control points. Full process validation documentation is available for regulatory submissions and third-party audits.
Manufacturing Capability
Procurement decisions require hard numbers. Here is exactly what KSNutripharma can deliver for your sulforaphane product line:
| Capability | Specifications | Notes |
| Annual Capsule Capacity | 500 million capsules | Multiple encapsulation lines; flexible scheduling |
| Annual Powder Capacity | 200 metric tons | Dedicated blending suites for heat-sensitive actives |
| Humidity-Controlled Workshop | RH maintained at < 30% | Dedicated sulforaphane production suite |
| Nitrogen Packaging Line | Residual O2 < 3% | Automated flushing with inline oxygen monitoring |
| HPLC Laboratory | Shimadzu / Agilent systems | In-house glucoraphanin and sulforaphane quantification |
| LC-MS/MS Laboratory | Triple-quadrupole MS | Definitive sulforaphane identification and quantification |
| Particle Size Analysis | Laser diffraction (0.1-2000 um) | Blend uniformity and dissolution optimization |
| Accelerated Stability Chambers | ICH Q1A compliant | 40 degrees C / 75% RH and 25 degrees C / 60% RH conditions |
| Batch Traceability | ERP-integrated (SAP) | Full chain: raw material to finished goods to customer |
| Quality Control Laboratory | In-house; 24-hour turnaround | Every batch tested before release |
| Stage | Timeline | Key Deliverables |
| 1. Inquiry | 1–3 days | Requirements document; initial feasibility assessment |
| 2. Formula & Quotation | 3–7 days | Custom formula proposal; pricing; regulatory pathway review |
| 3. Sample | 1–2 weeks | Physical sample with COA; organoleptic evaluation |
| 4. Pilot Batch | 2–3 weeks | 1–10 kg powder or 5,000–50,000 units; stability samples retained |
| 5. Scale-Up | 3–4 weeks | Process parameter lock; equivalence data; batch record validation |
| 6. Commercial Production | Per schedule | Full-scale manufacturing; in-process controls; finished product testing |
| 7. QC Release & Delivery | 1–2 weeks | Final COA; regulatory documentation; export logistics |
KS Nutripharma applies Quality by Design principles to every sulforaphane project. We define Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) at project initiation, ensuring quality is engineered into the product — not tested in at the end.
Critical Quality Attributes (CQAs)
| CQA | Target | Test Method | Frequency |
| Glucoraphanin Assay | ≥ 95% of label claim | HPLC-UV | Every batch |
| Myrosinase Activity | ≥ 90% | Spectrophotometric assay | Every batch (if included) |
| Sulforaphane Equivalent | ≥ 90% of the label claim | LC-MS/MS | Every batch (pre-activated) |
| Moisture Content | < 5.0% | Karl Fischer titration | Every batch |
| Water Activity (aw) | < 0.60 | Water activity meter | Every batch |
| Oxygen Headspace | < 3.0% | Headspace gas analyzer | Every batch (nitrogen-flushed) |
| Capsule Fill Uniformity | RSD < 6.0% | Gravimetric (n=20) | Every batch |
| Dissolution | ≥ 80% in 30 minutes | USP <711> | Stability batches |
Critical Process Parameters (CPPs)
| CPP | Control Range | Monitoring Method |
| Blending Time | 15-30 minutes (formulation-specific) | Automated timer; batch record |
| Relative Humidity | < 30% RH during all operations | Continuous RH sensor; alarm system |
| Processing Temperature | < 35 degrees C for all operations | Infrared thermometer; data logger |
| Nitrogen Purity | ≥ 99.9% N2 | Inline oxygen analyzer |
| Packaging Integrity | No leaks; seal strength validated | Vacuum leak test; seal strength tester |
| Blender Shear Rate | Low-shear protocol for enzyme products | Speed setting; validated protocol |
Risk Assessment & Risk Control
Every sulforaphane manufacturing project at KSNutripharma begins with a formal risk assessment. We identify potential failure modes, evaluate their impact on product quality and patient safety, and implement controls before manufacturing begins.
| Potential Risk | Impact | Mitigation Strategy | Verification |
| Raw Material Variation | Inconsistent glucoraphanin potency; batch failures | Approved supplier program; incoming HPLC QC; multi-batch qualification | COA review; retention sampling |
| Humidity During Processing | Sulforaphane degradation; potency loss | Dedicated dehumidified suite; continuous RH monitoring; alarm system | Environmental monitoring logs |
| Oxidation During Packaging | Sulfur moiety oxidation; off-odors; potency loss | Nitrogen flushing (< 3% residual O2); oxygen-barrier packaging | Headspace O2 analysis every batch |
| Myrosinase Inactivation | Reduced conversion efficiency; efficacy loss | Temperature-controlled processing (< 35 degrees C); validated blending protocol | Enzyme activity assay at release |
| Cross-Contamination | Allergen or residue carryover | Dedicated equipment and suite; validated cleaning protocols; swab testing | Cleaning validation; TOC swab results |
| Shelf-Life Drift | Label claim failure before expiry | Accelerated + real-time stability (ICH Q1A); trend analysis | Stability data review; shelf-life extrapolation |
| Packaging Integrity Failure | Moisture ingress; product degradation | Triple-barrier HDPE; welded desiccant; seal validation | Leak test; seal strength; visual inspection |
This risk-based approach is not a one-time exercise. Risk assessments are reviewed and updated at every product revision, complaint investigation, and annual product quality review (APQR).
Standard Batch Documentation
- Certificate of Analysis (COA)— Batch-specific test results for all specification parameters
- Product Specification— Complete quality specification with test methods and acceptance criteria
- Technical Data Sheet (TDS)— Product description, composition, physicochemical properties, handling guidelines
- Material Safety Data Sheet (MSDS)— Safety information, hazard classification, handling precautions, first aid
- Residual Solvent Report— GC-MS analysis confirming compliance with ICH Q3C limits
- Heavy Metal Report— ICP-MS data for Pb, Cd, As, Hg
- Microbiology Report— TAMC, TYMC, specified organism testing per USP <61>, <62>
- Stability Summary— Available stability data with storage conditions and retest period
Regulatory & Compliance Statements
- Allergen Statement— Free from major allergens; customizable per market requirements
- Non-GMO Statement— Available for non-GMO formulations
- BSE/TSE Statement— Free from bovine spongiform encephalopathy / transmissible spongiform encephalopathy risk materials
- Halal Certificate— Available upon request
- Kosher Certificate— Available upon request
- ISO 22000— Certified
- FSSC 22000— Certified
- cGMP Compliance— Per 21 CFR Part 111 (US) and applicable EU regulations
We provide end-to-end packaging services from primary container selection through finished goods kitting and shipment to your designated warehouse or 3PL.
Primary Packaging
- Amber glass bottles (30cc-240cc) with child-resistant caps — ideal for liquid and softgel products
- PET/HDPE bottles with induction seals — cost-effective for capsules and tablets
- Blister packs (PVC/PVDC, aluminum-aluminum) — retail and travel-friendly formats
- Stand-up pouches and single-serve sachets — powder and stick pack products
- Glass dropper bottles (30mL-120mL) — liquid formulations and functional shots
Label & Design Services
- In-house design team with supplement industry expertise
- Regulatory-compliant label review for structure/function claims
- Multi-language label capabilities (English, Spanish, French, German)
- Amazon FBA-compliant labeling and bundling
Secondary Packaging
- Retail cartons with UPC barcodes
- Display-ready case packaging
- Subscription box format optimization
We structure minimum order quantities to support brands at every stage of growth, from market testing to national retail distribution.
| Brand Stage | MOQ | Lead Time | Best For |
| Startup | 500-1,000 units | 6-8 weeks | Market testing, soft launch |
| Growing | 2,500-5,000 units | 5-7 weeks | Channel expansion |
| Established | 10,000+ units | 4-6 weeks | Scale production, retail |
Samples & Prototyping
- Pre-formulated samples: Free (shipping cost applies); 5-7 business days
- Custom formula prototype: $500-2,000; 2-3 weeks
- Pilot batch (minimum 100 units): Available for validation testing
Pricing Structure
Unit pricing is determined by order volume, dosage form complexity, and formula customization level. Pre-formulated products offer the most competitive pricing. Custom formulations include a one-time development fee of $500-2,000 depending on complexity and number of prototype iterations required.
Scaling Notes
Lead times assume formula finalization and packaging artwork approval. First-time custom formulations add 2-4 weeks for development and stability screening. Rush production may be available for established formulas — contact your project manager for scheduling.
How to Start a Sulforaphane OEM Project with KS Nutripharma?
Starting a Sulforaphane project does not require a finalized formula. An initial assessment can begin with the active system, target dose, dosage form, target market and estimated quantity. From there, the formulation and manufacturing team can determine technical feasibility, development requirements and the appropriate production route.
1. Tell Us What You Want to Develop
For an initial assessment, provide the key project parameters:
| Information | Examples / Options |
|---|---|
| Active system | Sulforaphane (SFN) · Glucoraphanin (GR) · GR + Myrosinase · Broccoli Sprout Extract |
| Target dosage | mg or μmol per serving |
| Dosage form | Capsule · Tablet · Powder · Stick Pack · Other |
| Delivery system | Standard · Liposomal · Capsule-in-Capsule · Open to recommendation |
| Target market | US · EU · UK · Canada · APAC · Other |
| Estimated quantity | Initial launch quantity or expected commercial volume |
| Packaging | Bottle · Blister · Sachet · Custom packaging |
| Additional ingredients | Vitamins · Minerals · Botanical extracts · Other actives |
Already have a formula? Send the formula or product specification directly.
Still at the concept stage? The active system, target dose, market and preferred dosage form are enough for an initial feasibility review.
2. Formula & Manufacturing Feasibility Review
Before a quotation is finalized, the proposed formula is reviewed for practical manufacturing requirements.
The review may include:
- Active specification and target assay
- Capsule size and estimated fill weight
- Powder density and flow characteristics
- GR + myrosinase compatibility where applicable
- Multi-ingredient compatibility
- Delivery-system requirements
- Processing and moisture considerations
- Packaging and stability requirements
- Target-market documentation requirements
If the proposed formula creates a technical constraint, the team can discuss alternatives such as a different capsule size, multiple-capsule serving, more concentrated raw material, formula adjustment or a different delivery system.
The objective is to identify technical constraints before the project reaches commercial production—not after a large production order has been placed.
3. Sample Development
Once the formula and specifications are agreed, laboratory or pilot-scale samples can be prepared for evaluation.
Depending on the project, sample review may cover:
- Appearance and capsule characteristics
- Target fill weight
- Powder flow and filling performance
- Active assay
- Blend uniformity
- Myrosinase activity for applicable formulas
- Basic physical characteristics
- Initial packaging considerations
Samples provide a practical checkpoint before moving to a larger production commitment.
4. Pilot & Process Confirmation
For formulas with higher technical complexity, a pilot or process-confirmation stage can be used to evaluate whether the laboratory formulation transfers effectively to the intended manufacturing process.
Particular attention may be given to:
- Mixing and blend uniformity
- Capsule filling or other dosage-form processing
- Active retention during processing
- Enzyme activity where applicable
- Moisture exposure
- Equipment and process parameters
- Scale-up considerations
Not every project requires the same level of pilot work. The development route depends on the formula, dosage form, production volume and technical risk.
5. Commercial Production & Quality Release
After formula, specifications, packaging and artwork are approved, the project moves into commercial manufacturing.
The production stage includes applicable:
Raw Material Release → Production → In-Process Controls → Finished-Product Testing → QA Review → Batch Release
Finished-product release may include active assay, microbiological testing, physical testing, content uniformity and other tests defined by the approved product specification.
A batch is released only after the required quality and documentation requirements have been completed.
6. Packaging, Documentation & Shipment
After QA release, the finished product proceeds through packaging and final shipment preparation.
Depending on the project, documentation can include:
- Certificate of Analysis (CoA)
- Product specification
- Batch production records
- Stability documentation
- Packaging specifications
- Regulatory support documents
- Export documentation
Packaging configuration is confirmed against the approved product and stability requirements rather than selected solely for appearance or branding.
What We Need for an Initial Quote
You do not need to prepare a complete technical package before contacting us.
For the fastest initial assessment, send:
1. Active: SFN / GR / GR + myrosinase / broccoli sprout extract
2. Target dose: mg or μmol per serving
3. Dosage form: capsule / tablet / powder / stick pack
4. Delivery system: standard / liposomal / capsule-in-capsule / open to recommendation
5. Target market: US / EU / UK / Canada / APAC / other
6. Quantity: estimated first order or annual volume
If you have an existing formula, specification or product artwork, you can include those as well.
Need Help Deciding the Right Sulforaphane System?
You do not need to know in advance whether your product should use free sulforaphane, glucoraphanin, GR + myrosinase, a standard capsule or an advanced delivery system.
Send us your target product concept and we can review the practical options based on dose, dosage form, ingredient compatibility, stability requirements, target market and production scale.
Request a Sulforaphane Formula Feasibility Review
Tell us your active system + target dose + dosage form + market + quantity.
[Request a Sulforaphane OEM Assessment →]



